Agennix Receives Broad Patent Covering Production of Human Lactoferrin in Eukaryotic Cells

Houston, TX -- May 10, 2001 -- Agennix, Incorporated, a developer of protein and peptide-based drugs targeting oncology, infectious disease and dermatology, today announced the issuance of a patent broadly covering the method for expressing human lactoferrin in eukaryotic cells. The patent, U.S. Patent No. 6,228,614, broadens the Company's previous patent coverage to include a greater variety of potential production systems for this protein. The patent is assigned to the Baylor College of Medicine and is licensed exclusively to Agennix. The issuance of this patent brings to Agennix 13 U.S. patents in its growing portfolio. Corresponding patents have now been granted in many countries throughout the world..

"This patent significantly expands our patent coverage of recombinant human lactoferrin," said Richard Barsky, CEO of Agennix. "The issuance of this patent confirms our view that Baylor scientists have made substantial contributions in the field of lactoferrin. These contributions are now being recognized by patent offices worldwide."

The inventors on the patent are Drs. Orla Conneely, Bert O'Malley, both on Agennix's Scientific Advisory Board, and Denis Headon, President and Chief Scientific Officer of Agennix.

Agennix is a privately-owned biopharmaceutical company focused on research and development of recombinant human lactoferrin (rhLF), a natural and safe anti-infective and anti-inflammatory protein, and a variety of related peptides. Holding 40 issued patents and 84 pending patents, the Company is engaged in programs that address large market opportunities and unmet medical needs in the areas of oncology, infectious disease and dermatology. Agennix has completed numerous pre-clinical and clinical trials with rhLF demonstrating the enormous potential of lactoferrin in a wide range of clinical conditions. More information about Agennix is available on the Company's web site at: www.agennix.com.